We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Rapid Diagnostic Test for Brain Tumors to Reduce Need for Invasive Surgical Biopsy

By LabMedica International staff writers
Posted on 20 Jun 2024
Print article
Image: The cerebrospinal fluid test decreases time to diagnosis for brain tumors (Photo courtesy of Shutterstock)
Image: The cerebrospinal fluid test decreases time to diagnosis for brain tumors (Photo courtesy of Shutterstock)

Most brain and spinal cord tumors are diagnosed in the hospital setting, often after patients exhibit rapidly progressing deficits. Given the urgency, the traditional delays and risks associated with neurosurgical biopsies can hinder prompt diagnosis and treatment of central nervous system (CNS) tumors. Researchers have now developed a rapid genotyping test for patients presenting with CNS lesions, which has eliminated the need for invasive surgical biopsies in seven cases, reducing the time to diagnosis from 10 days to just 2.

The rapid genotyping test developed by a collaborative team of neurosurgeons, oncologists, and pathologists at Mass General Brigham (Somerville, MA, USA) identifies genetic markers of various CNS tumors from cerebrospinal fluid (CSF), gathered during a lumbar procedure. This test not only speeds up the diagnosis but also avoids the need for more invasive brain biopsies in some cases. The team utilized a method called TetRS (Targeted Rapid Sequencing) in a study involving 70 patients with newly identified CNS lesions of unknown origin. The development of TetRS dates back almost a decade when researchers identified a few genes frequently mutated in specific brain cancers. By 2015, they demonstrated that these genetic mutations could be detected in tissue samples removed during surgery, and by 2021, they successfully applied TetRS to cerebrospinal fluid.

In their latest study, the researchers tested TetRS in real-world situations where patients might arrive in the Emergency Department with an abnormal lesion that could be either from a tumor or benign. The study aimed to verify that TetRS could expedite accurate diagnoses without the risk of false positives. TetRS was specifically designed to identify genetic signatures indicative of brain cancer, focusing on mutations in genes such as MYD88, TERT promoter, IDH1, IDH2, BRAF, and H3F3A. Of the 70 patients evaluated, 33 were eventually diagnosed with neoplasms. TetRS alone diagnosed six of these patients, and when combined with traditional diagnostic approaches, it identified an additional eight, achieving a sensitivity of 42%. For the 37 patients not diagnosed with neoplasms, TetRS reported no false positives, demonstrating a specificity of 100%. 

The use of this rapid genotyping test not only eliminated the need for surgical biopsies in seven cases but also significantly reduced the average time to treatment initiation, from 12 days to just 3 days. The results of the latest study were published in the American Society of Hematology's Blood journal on May 22, 2024. The researchers acknowledge that more extensive studies are necessary to confirm the broader applicability of these findings and to assess the clinical impact of earlier diagnosis and treatment. TetRS is now clinically available across the Mass General Brigham network, with the Mass General Brigham Pathology department processing samples from MGH, Brigham and Women’s Hospital, and other locations across the U.S.

“By working together across pathology, neuro-oncology and neurosurgery teams, we’ve developed an innovative, collaborative way to improve patient care,” said co-author Deborah Forst, MD, of the Mass General Cancer Center. “The ability to rapidly detect tumor-related molecular variants in patients’ spinal fluid samples has allowed us to promptly draw diagnostic conclusions through less invasive testing and to initiate individualized and potentially life-saving chemotherapies in rapid fashion.” 

Related Links:
Mass General Brigham

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Dengue Virus Test

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.